Global Alzheimer’s Pipeline Drugs Market Size, Share and Trends Analysis Report, By Type (Namenda, Ebixa, Axura, Aricept, Noortropil, Excelon, Memary, Solanezumab, LuAe58054), By Application (Hospital, Drug Store), Forecast (2022-2028)

The global alzheimer’s pipeline drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Diabetes, obesity, heart disease, and high blood pressure (BP), along with a sedentary lifestyle, unhealthy diet, and smoking, are some of the major factors that leads to an increase in the development of Alzheimer’s disease. The increase in the prevalence of Alzheimer’s disease has created demand for the development of new drugs for its treatment which in turn driving the global alzheimer’s pipeline drugs market growth. In addition, leading pharmaceutical companies are focusing on the development of drugs for Alzheimer’s treatment. The market growth is driven by the strong focus of the pharmaceutical companies and research organizations on the R&D of drugs for alzheimer’s drug; creating a strong pipeline for effective therapy.

 

The development of a potential treatment for alzheimer’s disease is commonly known as DA drug development. However, many companies are investing heavily in finding a cure and preventing alzheimer’s disease permanently. Therefore, the market for this drug development seems to be an excellent investment opportunity. Growth in the technology sector also helps in the search. The opportunities look good with the alzheimer’s Pipeline Drug market. The DA drug exists because of people with Alzheimer’s, who almost always come from older people. Therefore, districts with high rates of young people or adults will attract a greater need for these drugs. In April 2019, the Alzheimer’s Drug Discovery Foundation announced a diagnostics accelerator program that aims to track the development of digital tools for alzheimer’s disease and dementia. Such public and private initiatives across the globe are positively affecting the market growth.

 

Some major players in the market include AbbVie Inc., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly & Co., Takeda Pharmaceutical Co. Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in December 2018, Eli Lilly & Co. and AC Immune collaborated to develop a new treatment for alzheimer’s disease using AC Immune’s Morphomer platform. This collaboration is expected to promote the growth of the global alzheimer’s pipeline drugs market.

 

Market Coverage

 

  • The market number available for – 2021-2028
  • Base year- 2021
  • Forecast period- 2022-2028
  • Segment Covered-
    • By Type
    • By Application
  • Regions Covered-
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World

 

  • Competitive Landscape-AbbVie Inc., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly & Co., Takeda Pharmaceutical Co. Ltd., among others.

 

Key questions addressed by the report

 

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • How has COVID-19 impacted the market?
    • Deviation from the pre-COVID-19 forecast
    • Most affected region and segment
  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

 

Global Alzheimer’s Pipeline Drugs Market Report by Segment

 

By Type

  • Namenda
  • Ebxia
  • Axura
  • Aricept
  • Nootropil
  • Exelon
  • Memary
  • Solanezumab
  • LuAe58054

By Application

  • Hospital
  • Drug Store

 

Global Alzheimer’s Pipeline Drugs Market Report by Region

 

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific

Rest of the World

  • Latin America
  • Middle East & Africa

The report will be delivered within 48-72 hours after payment confirmation